Lanean...
Hitting KRAS When It’s Down
KRAS, one of the most prevalent oncogenes and sought-after anticancer targets, has eluded chemists for decades until an irreversible covalent strategy targeting a specific mutation (G12C) paved the way for the first KRAS inhibitors to reach the clinic. MRTX849 is one such clinical candidate with pro...
Gorde:
| Argitaratua izan da: | J Med Chem |
|---|---|
| Egile Nagusiak: | , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
American Chemical
Society
2020
|
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7467708/ https://ncbi.nlm.nih.gov/pubmed/32568546 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.jmedchem.0c00785 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|